Introduction
Since 1970, the UK Medical Research Council (MRC) Working Party on Childhood Leukaemia has conducted a series of therapeutic trials for acute lymphoblastic leukaemia (ALL). In the time period between 1980 and 2001, 80-95% of all patients presenting with ALL in the ages 0-15 years were enrolled into the four consecutive trials described in this paper. Reasons for non-entry included individual centres piloting succeeding trials, an alternative national trial existing for specific subtypes of leukaemia (for example, infant leukaemia post-1992 and B-cell ALL from 1985), and following individual family or physician preference.
By 1972, broad principles of therapy were established, and in a series of trials (UKALL II-VII), various aspects of the basic protocol were tested. The results were generally disappointing; fewer than 50% of the 1470 patients enrolled into the MRC studies between 1972 and 1979 remained in first remission after 4 years. 1 UKALL VII (1979 -1980 yielded somewhat better results for a small group of standard-risk patients, 2 but was still less impressive than the results emerging at that time from the Berlin/Frankfurt/Munster group (BFM) 3 and certain American trials. 4 These disappointing results led to a collaboration with the United States Children's Cancer Group (CCG), who gave permission for the UK Working Party to use protocol CCG 162 (specifically arm 1A) as the standard MRC therapeutic protocol. The initial phase was designated as the UKALL VIII study; after the first year, two randomizations were introduced and this latter phase was designated as the UKALL VIII trial. 5 The trial reported the single greatest improvement in event-free survival (EFS), compared with the historical groups, seen in the United Kingdom up to that time. 1 The results emphasized the value of international sharing of information and collaboration.
The subsequent MRC study, UKALL X, 6 evaluated the effects of a short, very intensive module of treatment given early, late, or both, or omitted completely. Ultimately, this trial showed that there was a major advantage to having both early and late intensification. UKALL XI attempted to extend this philosophy by examining the contribution of a third intensification, 7 which was of the prolonged, reinduction-reconsolidation style, developed by the BFM group. It also attempted to evaluate the role of different forms of central nervous system (CNS)-directed therapy. 8 Randomization to receive or not the third intensification was carried over into the following trial, namely, ALL97, which also examined the roles of different steroids 9 and thiopurines 10 by randomizing prednisolone against dexamethasone and mercaptopurine against thioguanine. Ultimately, although the third intensification provided an advantage, 7 the overall results of UKALL XI were not an improvement over UKALL X. 11 In addition, it was clear that the outcome for children in the United Kingdom, especially those with high-risk disease, were lagging behind the results obtained by other cooperative groups. As a result, the UKALL treatment programme was revised to mimic more closely that used by the Children's Oncology Group, with a second revised phase of ALL97, referred to as ALL97/99. 12 This study was closed in 2001 and its results are included in this updated long-term follow-up report.
Patients and methods
From 1980 to 2001, 6516 consecutive patients, aged 15 years or younger, with de novo ALL were enrolled into four successive treatment protocols (UKALL VIII, X, XI and ALL97; UKALL IX being for adult patients only). A total of 54 patients were not eligible because of wrong diagnosis or because of the subtype of leukaemia, for example, mature B-cell leukaemia, for which an alternative UK strategy was available. Thus, 6462 eligible patients were treated in the four trials (UKALL VIII, 825; UKALL X, 1612; UKALL XI, 2090; and ALL97, 1935).
Diagnosis in all four trials was based on standard local hospital morphological review by an expert haematologist, supported by a centralized review panel that also reviewed early response and all marrows from reported non-remitting patients. 13 Early response was defined by percentage of marrow blasts at day 15 in UKALL VIII and X; at day 8 in UKALL XI; and at day 8 or 15, depending on the treatment arm, in ALL97/99.
A standard immunophenotyping panel has been used in all MRC trials and patients have been classified into the following groups:
(1) Early pre-B or nullFbased on CD10 negativity, CD19 positivity, tdt positivity and T-cell marker negativity. (2) Common ALLFbased on CD10 positivity, CD19 positivity, tdt positivity or T-cell marker negativity. (3) Pre-BFthe same as common ALL, but also with cytoplasmic immunoglobulin positivity. (4) T-cell diseaseFclassified by CD2 and/or CD7 positivity, and CD19 and HLA-DR negativity. (5) An unusual category has always been identified by patients who expressed the so-called myeloid antigens, either CD13 or CD33. (6) Finally, other patients whose antibody profile did not fit into any of the above five categories.
It has been consistently possible to divide the great majority of ALL cases into either B-cell or T-cell lineage, and it is these broad categories that have been used in a uniform manner for consistency in this series of trials. 14 Only mature B-cell ALL patients (surface immunoglobulin positive) have been excluded from any of the trials on the basis of immunophenotype.
With an increasing recognition of its importance, the development of chromosomal banding techniques, the introduction of fluorescence in situ hybridization (FISH) to identify specific translocations and the review and central collection of cytogenetic/FISH data into a bespoke cytogenetics database, 15 the rate of successful cytogenetic analysis requested and performed has improved over the 21-year period. Cytogenetic analysis was performed successfully on 281 (34%) patients in UKALL VIII, 5 830 (51%) patients in UKALL X, 16 1658 (79%) patients in UKALL XI 7 and 1728 (91%) patients in ALL97. 17 In the United Kingdom, FISH was the chosen molecular method for the routine detection of chromosomal abnormalities of prognostic significance, which was implemented in ALL97. There was specific emphasis on the poor-risk abnormalities, t(9;22)(q34;q11.1)/BCR-ABL1 fusion and rearrangements of the MLL gene, particularly t(4;11)(q21;q23), used for risk stratification in this trial. 15 The four MRC protocols were designed by a working group of coordinators, modified and approved by the full Childhood Working Party and then subjected to independent peer review, first by a leukaemia trials steering committee and then by a separate data monitoring and ethical committee. Approval for individual patient entry was subject to local research ethical committee review for each participating hospital centre. Parent or patient consent was obtained before trial entry, as required by the ethical procedures relevant at the time the trial was in progress.
Treatment
The four studies have all been previously described elsewhere, [5] [6] [7] [8] [9] [10] [11] [12] but are summarized briefly here so that the continuing themes and changes in strategy can be highlighted.
UKALL VIII (1980) (1981) (1982) (1983) (1984) . This study 5 aimed to reproduce directly the more favourable results being reported by CCG. All children with ALL, aged 0-14 years inclusive, were eligible. A total of 825 patients were analyzed. In the first year (designated UKALL VIIIS), from September 1980 to October 1981, all patients irrespective of their initial prognostic features received a three-drug induction regimen of weekly vincristine (1.5 mg/m 2 /dose for 5 days), 28 days of oral prednisolone (40 mg/m 2 per day) and nine intramuscular injections of asparaginase (6000 IU/m 2 /dose) administered thrice a week for 3 weeks. Initially, Escherichia coli asparaginase (Merck, Sharp, Dohme, Whitehouse Station, NJ, USA) as per the CCG 162 protocol 4 was used, and subsequently, Erwinia asparaginase was administered at the same dosage. 18 From November 1981 until the trial closed in December 1984, a randomization was introduced for patients to receive two doses of daunorubicin (45 mg/m 2 per dose) intravenously (i.v.) on days 1 and 2 of induction (arm B) or not (arm A, which was, consequently, identical to UKALL VIIIS). CNS-directed therapy for all patients consisted of intrathecal (i.t.) methotrexate (dosage based on age) 19 on days 0, 15 and 28, and then thrice weekly during cranial irradiation (18 Gy in 10 fractions) given immediately after achievement of remission. 6-Mercaptopurine was given at a dose of 75 mg/m 2 per day orally throughout CNS irradiation therapy, and continued along with weekly oral methotrexate (20 mg/m 2 ) in continuing therapy, together with monthly pulses of i.v. vincristine (1.5 mg/m 2 ) and 5 days of oral prednisolone (40 mg/m 2 /day).
Between September 1980 and December 1980, the duration of therapy was 2 years from the time of remission, but subsequently, from January 1981 to the close of the trial in December 1984, there was a second randomization for those patients still in remission at 2 years, between 2 and 3 years of continuing therapy from achievement of remission. Those patients who were not in remission at day 29 were given two further weeks of vincristine and prednisolone, but thereafter were considered off-protocol if not in complete remission. UKALL X (1985) (1986) (1987) (1988) (1989) (1990) . This trial 6 was designed to test the benefit of post-remission intensification, and was open to all children aged 0-14 years, except for those with surface membrane immunoglobulin-positive B-cell ALL. A total of 1612 eligible patients were enrolled. Induction therapy was identical to UKALL VIIIB (vincristine, prednisolone, daunorubicin and Erwinia asparaginase (6000 IU/m 2 , thrice weekly for 9 weeks), together with i.t. methotrexate on days 1, 15 and 29). Bone marrow response was again centrally assessed at day 15.
Patients were randomized to receive no intensification block (arm A); an early block at week 5 (arm B); or a late block at week 20 (arm C); or both an early and late block (arm D). The philosophy of the MRC group has been to carry forward the best arm of each trial as the standard arm of the next. Therefore, arm A was the same as UKALL VIIIB. The composition of the two intensification blocks was identical and consisted of a 5-day course of cytarabine (10 doses of 100 mg/m 2 , given every 12 h i.v.), etoposide (100 mg/m 2 daily i.v. for 5 days), thioguanine (80 mg/m 2 orally daily for 5 days) plus two further doses of daunorubicin (45 mg/m 2 /dose on days 1 and 2), one dose of vincristine (1.5 mg/m 2 i.v., day 1) and 5 further days of prednisolone (40 mg/m 2 /day tapering over 3-4 days after the early block). Intrathecal methotrexate was given on day 1 of each block. Moderate-to-severe pancytopenia was observed at 7-10 days, and recovery adequate to permit resumption of therapy did not occur until 3-4 weeks later. 20 The CNS-directed therapy phase was the same as in UKALL VIII (18 Gy cranial irradiation plus three i.t. injections of methotrexate). Oral 6-mercaptopurine was given daily (75 mg/m 2 /day) during irradiation to all patients.
Exceptions to the randomization process included the following:
(1) Patients with CNS disease at diagnosis, as defined by the presence of more than five blast cells per ml in the CSF that were recognizable, who received arm B (early intensification) followed by 24 Gy cranial irradiation, and 12 Gy irradiation to the spine, and then continuation therapy with no further intensification modules. (2) Children with a white cell count 4100 Â 10 9 cells/l at diagnosis were allocated to arm D and received cranial irradiation up to a dose of 24 Gy unless they had a matched sibling donor, in which case, cranial irradiation was replaced by cyclophosphamide and total body irradiation as conditioning regimen for bone marrow transplantation in first remission. 21 (3) From January 1985 to April 1988, females aged 2-9 years with an initial leukocyte count o20 Â 10 9 cells/l were allocated to arm A (that is, no intensification). From April 1988 onwards, these patients were entered into the randomized trial.
Continuing therapy was similar to that used in UKALL VIII.
UKALL XI (1990 XI ( -1997 . This trial recruited 2090 eligible patients aged 1-14 years inclusive (up to their 15th birthday) 7, 8, 11 . Induction therapy was identical to UKALL X until May 1992, when the two doses of daunorubicin were dropped from induction to reduce total anthracycline exposure to 180 mg/m 2 because of anxiety regarding late cardiotoxicity being reported at that time. 22 Initially, all patients, except those with CNS disease at diagnosis (who were treated with modified UKALL XB, and from 1994 onwards a modified UKALL XD regimen), were randomized between regimens UKALL XC and UKALL XD. In May 1991, an interim analysis showed benefit for two intensification modules, and hence, all new patients were allocated to the UKALL X arm D (two intensification modules at weeks 5 and 20), and from May 1992, all new patients were randomized between two and three intensification modules; this change coincided with the omission of anthracycline from the induction regimen. The third intensification block was given between weeks 35 and 42, and differed from the previously used pulses in being a BFM-style phase with reinduction and reconsolidation. Between intensification pulses and for a total of 2 years, oral daily 6-mercaptopurine (75 mg/m 2 /day), weekly oral methotrexate (20 mg/m 2 /dose) and monthly pulses of 5 days of prednisolone (40 mg/m 2 /day) and a dose of vincristine (1.5 mg/m 2 /dose) were given as continuing therapy.
Patients with an initial peripheral blood white cell count (WCC)o50 Â 10 9 cells/l were randomized to receive either a long course of i.t. methotrexate alone or high-dose systemic methotrexate in a dose of 6-8 g/m 2 (those under 4 years of age having 8 g/m 2 and those older having 6 g/m 2 ) at weeks 6, 8 and 10, 23 with four doses of i.t. methotrexate , the latter continuing throughout the remainder of the course of chemotherapy. Patients with an initial white count of X50 Â 10 9 cells/l were randomized between high-dose systemic methotrexate (6-8 g/m 2 ) with a long course of i.t. methotrexate, and cranial irradiation up to a dose of 24 Gy (in 15 fractions of 1.6 Gy per fraction) with a short course of i.t. methotrexate (7 doses). All i.t. doses were calculated on the basis of age. The results of randomizations are presented in Table 1 .
ALL97 and ALL97/99. These linked trials ran from April 1997 to June 2001 and were to determine the possible benefits of dexamethasone over prednisolone and of 6-thioguanine over 6-mercaptopurine. 9, 10, 12 The treatment schedule for the ALL97 phase was based on that of UKALL XI, with two intensification blocks, and continued with the UKALL XI randomization to a third intensification, as in the latter stage of UKALL XI. This randomization was discontinued when it became clear that, although the third intensification offered an advantage, the outcomes for patients in UKALL XI, and particularly for those patients at highest risk of relapse, had not improved in the manner seen by other cooperative groups. 11 In 1999, the treatment schedule was modified to mimic that used in the United States by the Children's Oncology Group, and this phase was named ALL97/99. In essence, this change meant discontinuing the short (5 day), very intensive blocks used first in UKALL X and substituting it with the prolonged (7 week) BFM style of intensification. Other changes included initial stratification by age and WCC into standard (ageo10 years or WCCo50 Â 10 9 cells/l) and high-risk groups (ageX10 years or WCCX50 Â 10 9 cells/l). Standard-risk patients received three-drug induction, whereas those at high risk, in addition, received daunorubicin. Early assessment of response by examination of the bone marrow at day 15 (standard risk) and day 8 (high risk) was adopted, so that patients with 425% blasts at the assessment point were deemed to be slow early responders (SER) and were transferred to a more intensive regimen incorporating augmented BFM consolidation and extended intensification phases. In addition, boys were given 3 years of maintenance therapy, rather than 2 years, as had previously been the case, whereas girls continued to receive a total of 2 years of treatment, from the start of interim maintenance 1. CNS-directed therapy in both phases was a long course of i.t. methotrexate. Only patients with CNS disease at the time of diagnosis were irradiated. Patients were randomized at the time of diagnosis to receive either dexamethasone (6.5 mg/m 2 ) or prednisolone (40 mg/m 2 ) during induction and during all subsequent treatment phases in which prednisolone would conventionally have been included. They were also randomized to receive either 6-mercaptopurine (75 mg/m 2 ) or 6-thioguanine (40 mg/m 2 ) during consolidation and maintenance phases. These randomizations were continued throughout both phases of the trial until, in June 2001, the independent Data Monitoring Committee recommended that the trial should close because of the advantage of dexamethasone over prednisolone, consistent with confidentially supplied results from the parallel US COG trial.
During the ALL97 phase, there was a separate non-randomized studyFHR1 24 Ffor patients at high risk of relapse. Eligible patients were calculated to have a risk of relapse in excess of 30% on the Oxford Hazard score, 25 or to have highrisk cytogenetic features. This study was based on arm D of UKALL X, but with high-dose methotrexate inserted between the two intensification blocks. Thus, it had no induction dose of anthracycline and used only nine doses of Erwinia asparaginase. The results of randomizations are presented in Table 4 .
Statistical analyses
In these analyses, overall survival (OS) is defined as the time from diagnosis until death, censoring at date of last contact, whereas EFS is defined as the time from diagnosis until either relapse (haematological, CNS or other site or a combination thereof) or death due to any cause, whether or not the patient entered remission. Numbers of secondary tumours occurring as a first event are reported, but are not counted as events for EFS. Because the numbers are small, their inclusion does not materially change results, with 5-and 10-year EFS reduced by o1% in almost all cases. Time to an isolated CNS relapse was defined as the time from diagnosis to a CNS relapse without relapse at any other site, excluding patients who did not enter remission. Time to any CNS relapse includes both time to any isolated CNS relapse and to a CNS relapse in conjunction with relapse at any other site, occurring within 30 days of the CNS relapse. Analyses of CNS relapse were censored at relapse at other sites. Actuarial EFS, OS and time to isolated/any CNS relapse curves were calculated by the method of Kaplan and Meier. Results are given as percentage (standard error). Approximate confidence intervals (CI) can be calculated by subtracting and adding twice the standard error.
Results were considered in randomized patients aged 1 year or older at diagnosis, divided by cell lineage (Null cell or pre-B cell, T cell) and the Rome/National Cancer Institute (NCI) risk (standard risk, age 1-9 years with WBCo50 Â 10 9 cells per 100 ml; high risk, all other patients aged 10 years or more regardless of initial WCC, and all patients with initial WCCX50 Â 10 9 cells per 100 ml).
Patient follow-up in these trials was carried out by the individual participating physicians in their own centre, with an annual request for updated information for all trial entrants, carried out by the Clinical Trial Service Unit each October for at least 10 years after trial entry. The current analyses consider information from the most recent completed follow-ups (UKALL VIIIF2001, UKALL XF2007, UKALL XIF2007 and ALL97-2008). In addition, information on deaths is obtained from the UK national registration system. When a death is reported through this system for a patient not reported as ever having relapsed, the treating centre is contacted to determine whether the patient relapsed before death. Fewer than 1% of patients are lost to follow-up before 10 years. Figure 1 shows EFS by trial, and OS is shown in Figure 2 . Figure 3 shows cumulative isolated CNS relapse risk and Figure 4 shows rates for any CNS relapse. Figures 5 and 6 show EFS and OS in ALL97 and ALL97/99 by phase of trial. Table 2 shows the EFS at 5 and 10 years for each trial, overall and according to presenting features. There are few events beyond 10 years. Table 3 shows the EFS by NCI risk group and by immunophenotype.
Results
Protocol-specific treatment outcome UKALL VIII (1980-1984, 17-21 years of follow-up).
A total of 41 of the 825 patients enrolled failed induction (nonremitters plus deaths in induction), giving a 95% remission rate. There have been 56 (7%) deaths in remission, 6 from second malignancies, and EFS rates were 57% (1.7) at 5 years and 54% (1.7) at 10 years (see Table 2 ). A total of 14 patients suffered a second malignancy as a first event. OS was 71.5% (1.6) at 5 and 65% (1.7) at 10 years. The cumulative risk of isolated CNS relapse at 5 years was 9% (1.1) and that of any CNS relapse was 14% (1.3). For the 20 infants aged below 1 year at diagnosis treated on this protocol, EFS was 30% (10.2) at 10 years.
Patients who received an induction dose of daunorubicin (arm B) had a 6% rate of induction failure (non-remitters plus deaths), which was double that of arm A (3%). However, there were reductions in marrow, testicular and combined relapses (30% of all relapses arm B, 38% arm A; P ¼ 0.06, odds ratio 0.8 with 95% CI of 0.6-1.1), but not of isolated CNS relapse. Deaths in early remission were also higher in those receiving daunorubicin (8 versus 4% of remitters). As a consequence of these contrasting risks and benefits, there was no significant EFS or OS benefit of receiving daunorubicin. 26 A meta-analysis of all trials on addition of an anthracycline shows a small, nonsignificant EFS benefit for the inclusion of daunorubicin, but about two-thirds of the data are from UKALL VIII. 27 For the late randomization between 2 and 3 years of continuing therapy, more relapses were seen after stopping therapy at 2 years (P-value for relapse-free survival, 0.04), but this advantage was counterbalanced by a 4% death rate in remission associated with the longer course of therapy and a higher retrieval rate for patients relapsing after only 2 years of treatment. Consequently, there was no significant survival benefit for those receiving 3 years of continuing therapy on this trial. 28 Patients in this trial were not stratified for therapy on the basis of any initial presenting features. Although EFS was superior to all previous UKALL protocols and comparable with results of the CCG 160 series, there was a persistent adverse impact of gender (male sex), age below 1 year, age X10 years, excess blasts (45%) at day 15 and presenting WCCX50 (especially above 100) and, apparently, of T-cell lineage, although in this trial, that feature was not independent of the presenting WCC. UKALL X (1985-1990; 17-22 years of follow-up). A total of 40 of the 1612 patients enrolled failed induction (nonremitters plus deaths), giving a remission rate of 98%. There were 68 deaths in remission (4%), 18 after a second malignancy. A total of 30 patients suffered second malignancy as a first event. The EFS rates for the whole trial were 62% (1.2) at 5 years and 60% (1.2) at 10 years. OS was 77% (1.0) at 5 years, 71% (1.1) at 10 years and 59.1% at 15 years. The cumulative rate of isolated CNS relapse was 7% (0.7) at 5 and 10 years, and 12% (0.9) for any CNS relapse. For the 26 infants aged below 1 year at diagnosis, EFS was 27% (8.7) at 10 years.
In total, 1171 children were randomized to receive intensification at 5 weeks (arm B), 20 weeks (arm C), both (arm D) or neither (arm A). The 5-year EFS was 71% (2.7) for those receiving two blocks, compared with 62% (2.8) on arm C, 63% (2.8) on arm B and 57% (2.9) on arm A (without any intensification). At 10 years, the EFS on arms D, C, B and A were 67% (2.8), 58% (2.9), 62% (2.8) and 55% (2.9), respectively. The benefits of intensification therapy were seen irrespective of any clinical presenting features previously shown to influence outcome, such as age, gender and initial leukocyte count, with a 12% improvement in long-term EFS for those patients randomized to receive two courses of intensification therapy. Further analyses showed that all subgroups of children, without exception, benefited from double intensification.
In this study, age, leukocyte count and gender were the most significant prognostic features. Response to therapy was also important, as assessed by day 15 bone marrow blast percentages. The most significant adverse effect was noted for the 31 patients with M3 marrows at day 15 (32% EFS compared with 63% for those with an M1 marrow). There was little difference between patients with M1 and M2 marrows at day 15. As in UKALL VIII, children with common or pre-B ALL seemed to fare better than those with T-cell immunophenotype on univariate analysis, but after stratification for age, gender and leukocyte count, the immunophenotype was no longer significant.
Central nervous system disease at diagnosis did not confer an overall adverse prognosis on the 29 patients so identified in this trial. In total, 51% of patients had successful cytogenetic analyses and the group of patients with high hyperdiploidy had a more favourable outcome. There was a worse prognosis for those with t(4;11) and t(9;22). The 16 patients with t(1;19)(23;p13), thought at the time to be an unfavourable characteristic, had a more favourable outcome. 15 UKALL XI (1990-1997; 10-17 years of follow-up). Atotal of 14 of the 2090 children enrolled failed induction (nonremitters plus deaths), giving a remission rate of 99%. There were 42 deaths in remission (2%), of which 12 were due to second malignancies. A total of 16 patients suffered a second malignancy as their first event.
The EFS rate for the whole trial was 63% (1.1) at 5 years and 60% at 10 years, with an OS rate of 85% (0.8) at 5 and 79% (0.9) at 10 years. The cumulative risk of isolated CNS relapse was 7% (0.6) at 5 and 10 years and 15% (0.8) for any CNS relapse.
Following the change in protocol after May 1992, when the induction of daunorubicin was dropped, there was a retrospective analysis on the effects of daunorubicin induction. The first 1419 children in the trial were previously reported, of whom 342 received daunorubicin. 26, 29 In total, 44% of the recipients of daunorubicin completely cleared their marrow of blast cells after 8 days, compared with only 13% of nonrecipients (w 2 ¼ 158.2; P-valueo0.0001). In addition, 9% of patients who received daunorubicin and 15% of those who did not had more than 80% blasts at day 8 (w 2 ¼ 7.7; P-value ¼ 0.006). In both groups independently, the rate of disease clearance correlated with disease-free survival, but there was no significant difference in overall outcome when comparing the two groups with each other, either for disease-free or relapse-free survival. UKALL XI showed a disease-free survival benefit for those allocated the third block of intensification at week 35: 69% (1.7) versus 60% (1.8) at 5 years and 66% (1.7) versus 56% (1.8) at 10 years. The difference arose principally because of fewer bone marrow relapses among patients who received three intensification pulses (10-year bone marrow relapse rate 25 versus 34%). The third block did not significantly affect OS (82% (1.4) versus 79% (1.5)), as there seemed to be better salvage in patients who did not receive it. There was no evidence of any difference in EFS benefit endowed by the third block of intensification for specific subgroups defined by age, WCC, immunophenotype or international risk groups. The addition of data of patients in the succeeding trial ALL 97, who were also randomized between three and two blocks, gave the same outcome. 7 A total of 1513 patients with initial WCCs of o50 Â 10 9 cells per 100 ml were randomized between a long course of i.t. methotrexate and high-dose methotrexate, with subsequent i.t. therapy. There was no significant difference in EFS or OS for the two groups, nor was there any significant heterogeneity of treatment effect on groups by age, gender, immunophenotype or cytogenetic features. High-dose methotrexate was significantly better than i.t. methotrexate alone in preventing isolated CNS relapse (P ¼ 0.008; 3% (0.7) versus 7% (1.0) at 10 years) and preventing isolated plus combined CNS relapses (P ¼ 0.04; 11% (1.2) versus 15% (1.4) ). Non-CNS relapses and deaths in remission were similar with either treatment. In this group of patients, those with T-cell disease fared worse than those with a pre-B phenotype (53% (6.9) compared with 65% (1.3). The worse outcome was because of an increase in both CNS and non-CNS relapses, which occurred with both treatments and remained significant after adjustment for age, gender and initial WCC (P ¼ 0.03). 8 For the group of patients with initial WCCs of X50 Â 10 9 cells/l, who were randomized between high-dose methotrexate with continuing i.t. chemotherapy and cranial radiotherapy with a short course of i.t. chemotherapy, there was no significant difference in EFS. All CNS relapses in this high-risk group, both isolated and combined, were reduced in the radiotherapy arm (P ¼ 0.08), with a cumulative actuarial incidence at 10 years of 19% (3.5) for radiotherapy compared with 28% (4.0) for highdose methotrexate. There were fewer isolated CNS relapses in the radiotherapy group, although this difference was not significant, but this advantage was offset by a non-significant increase in the number of non-CNS relapses. As a consequence, there was no significant difference in EFS and OS between the treatment arms, nor was there significant heterogeneity of effect by age, gender, immunophenotype or cytogenetic features.
In contrast to T-cell patients with WCCs o50 Â 10 9 cells/l, T-cell patients with initial WCCs in excess of 50 Â 10 9 cells/l fared as well as those with a pre-B phenotype, regardless of the treatment received.
In the low white cell group, the incidence of isolated testicular relapse was 6.3% (1.0), with one relapse occurring beyond 10 years, and in the high white cell group, the incidence was 6.4% (2.1), with no evidence of randomized treatment effect in either group.
The adverse prognostic significance of male sex, age X10 years and WCCX50 Â 10 9 cells/l persisted in this trial, as did the presence of t(9;22) and t(4;11) (see Table 2 ). T-cell lineage per se was significant in univariate analysis, but not when stratified by WCC, age and gender. CNS disease at diagnosis was not of prognostic significance.
ALL97 (1997-2002; 6-11 years of follow-up). A total of 1948 patients were registered in the trial between January 1997 and June 2002, 13 of whom were subsequently excluded because of incorrect diagnoses, leaving a total of 1935 patients for further analyses. There were 24 induction failures, giving a remission rate of 99%, and 66 deaths in remission (4%), of which 5 were from secondary tumours. A total of 11 patients suffered a secondary tumour as their first event. The EFS for the whole trial was 77% (1.0) at 5 years and 74% (1.0) at 10 years, and OS was 86% (0.8) and 83% (0.9), respectively. The isolated CNS relapse rate was 4% (0.5) and the rate of any CNS relapse was 7% (0.6) at 5 and 10 years. 9 In this trial routine, FISH screening for important chromosomal abnormalities with prognostic significance was introduced. This approach ensured that patients with high-risk abnormalities, BCR-ABL1 fusion and t(4;11), were identified in all cases, including those with a normal karyotype and failed cytogenetic result. The good risk associated with high hyperdiploidy was confirmed and the favourable risk abnormality, t(12;21)(p13;q22)/ ETV6-RUNX1 (TEL-AML1) fusion, was accurately detected in 22% of patients.
A total of 997 patients were treated in the ALL97 phase (846 treated on ALL97 and 151 very high-risk patients treated on HR1 24 ), and 938 were in the ALL97/99 phase. Of the 938 patients in ALL97/99, 578 (62%) were initially treated with regimen A and 360 (38%) with regimen B. A total of 21 regimen A patients and 133 regimen B patients were transferred to regimen C because of SER or unfavourable cytogenetic abnormality, so that, overall, 557 were treated with regimen A (standard risk), 227 with regimen B (high risk) and 154 with regimen C (very high risk). Of this latter group, 112 were considered to be at very high risk solely because of a SER to induction chemotherapy; 40 patients had high-risk cytogenetic abnormalities, 13 of whom also had a SER. Two patients had M2 marrows at day 29, but were not SER and did not have high-risk cytogenetics.
Diagnostic characteristics were similar between the two phases, but a greater proportion of patients in ALL97 were not randomized for steroid (20 versus 13%; Po0.0001), and of these, only one patient in ALL97 received dexamethasone by choice compared with 15 in ALL97/99.
Among the 1603 randomized patients, those allocated dexamethasone had half the risk of an isolated CNS relapse (P ¼ 0.001; 2.2% (0.5) versus 5.3% (0.8)). Both CNS relapse and non-CNS relapse (P ¼ 0.005; 11% (1.2) versus 16% (1.4)) were reduced. EFS was significantly improved with dexamethasone (P ¼ 0.0002; 83% (1.2) and 81% (1.4) versus 76% (1.5) and 73% (1.6) at 5 and 10 years, respectively), with no evidence of differing effects in any subgroup of patients. The use of dexamethasone throughout treatment led to a decrease in the risk of relapse for all risk groups of patients. 9 A total of 1493 patients were randomized between thioguanine and mercaptopurine during interim maintenance and continuing therapy, with all patients receiving thioguanine in the intensification phases. There was no difference in EFS or OS between the two arms. Although 6-thioguanine halved the risk of isolated CNS relapse compared with 6-mercaptopurine (P ¼ 0.02; 2.5% (0.6) versus 5% (0.8)), the benefit was offset by an increased risk of death in remission (P ¼ 0.01; 4% (0.7) versus 2% (0.5)), mainly owing to infections during continuing therapy. In addition, 95 patients developed veno-occlusive disease of the liver. Of this group, 85 were randomly assigned 6-thioguanine, representing 11% of all 6-thioguanine recipients. Longer-term follow-up revealed that 5% of 6-thioguanine recipients had evidence of non-cirrhotic portal hypertension because of periportal liver fibrosis or nodular regenerative hyperplasia. 10 Outcome by phase of trial Both EFS ( Figure 5 ; P ¼ 0.0009) and OS ( Figure 6 ; P ¼ 0.004) were significantly better in ALL97/99 than in ALL97 (80.0% (1.3) versus 74.0% (1.4) and 88.0% (1.1) versus 83.5% (1.2), respectively at 5 years). ALL97 showed an improvement in EFS, but not in OS, compared with the previous trial, UKALL XI.
The risk of isolated CNS relapse for patients in ALL97/99 was significantly lower than that for patients in ALL97 (P ¼ 0.04), with a 5-year isolated CNS relapse rate of 3.0% (0.6) for the former compared with 4.9% (0.7) for the latter. The overall CNS relapse rate was also significantly less for ALL97/99 (Po0.00005; 4.4% (0.7) versus 9.6%(1.0) at 5 years). There were no significant differences in the rates for non-CNS relapse, induction deaths or deaths in remission between the two phases of the trial. 12 The use of two phases of differing, although related, types of treatment permits a non-randomized comparison of the effects of various presenting features, such as gender, age group, WCC group, immunophenotype and thiopurine type, to determine whether there were significant differences between the relative effects within these subgroups. For all disease-related outcomes, there was no evidence of a difference in effect, with one possible exception. There was a suggestion that the relative risk reduction for isolated CNS relapse with ALL97/99 might be greatest for those aged 10 years and above (P-value for heterogeneity ¼ 0.03); however, because of the large number of statistical tests carried out, this result cannot be regarded as statistically significant and should be interpreted as a chance effect.
In total, 127 patients had CNS relapses, of which 72 were isolated CNS relapses. The actuarial isolated CNS relapse rate in ALL97/99 patients randomized to dexamethasone was only 1.8% (0.7) at 5 years compared with 3.7% (1.0) in patients randomized to prednisolone. These rates are much lower than those reported in previous trials that used cranial radiotherapy for CNS-directed therapy. The incidence of isolated CNS relapse in ALL97/99 was reassuringly low, even for subgroups perceived to be at higher risk of CNS relapse, such as in those patients with WCC4100 Â 10 9 cells/l (4.8%) or with T-cell phenotype (3.8% (2.2)), despite restricting the use of cranial radiotherapy only to those patients with overt CNS disease (CNS 3, o5% of all patients).
There were 38 patients presenting with CNS disease at diagnosis, 18 (1.8%) in ALL97 and 20 (2.1%) in ALL97/99. Of the 18 patients, 6 in ALL97 with CNS disease at diagnosis were treated on ALL-HR1, that is, they had other high-risk features at the time of diagnosis. A total of 5 of the 20 ALL97/99 patients were standard-risk patients and 15 were high-risk patients. By the end of the follow-up period (31 October 2008), 7 of the 18 ALL97 patients with CNS disease at diagnosis had died and 2 further patients had received a bone marrow transplant (one related donor, one unrelated donor). Out of the 20 ALL97/99 patients, 7 had died and 1 patient had suffered an isolated bone marrow relapse, followed by an unrelated donor bone marrow transplant.
Patients in ALL97/99 who were transferred to regimen C, either because of SER or because of high-risk cytogenetics only, still had a relatively poor prognosis, with an EFS at 5 years of 58.8% (4.0) (SER 58.9% (4.4), high-risk cytogenetics 58.6% (9.1)).
In the ALL97/99 phase of the trial, there was no significant difference in proportion with SER by randomized steroid. Excluding patients who were transferred to regimen C solely because of high-risk cytogenetics or M2 marrow at day 29, 46 (12%) patients randomized to dexamethasone, compared with 58 (15%) randomized to prednisolone, were transferred to C because of a SER, P ¼ 0.2. Table 3 shows EFS at 5 and 10 years by the Rome/NCI criteria and lineage for all patients treated in each time period on the relevant trial. Patients with an indeterminate lineage are also excluded from this table.
Treatment results by the Rome/NCI criteria and lineage in each era
The proportion of patients defined as standard risk by the NCI criteria in these trials is 65-70% and that of high risk is 30-35%. The 5 and 10-year EFS has progressively improved in each consecutive trial for standard-risk B-cell lineage ALL. NCI criteria have clearly delineated those with a B-cell lineage and a more adverse outcome, but for high-risk patients, survival did not improve during the period between 1980 and 1997, but improved with the advent of ALL97/99. For T-cell ALL, the criteria clearly defined a less favourable prognostic group only in UKALL X. There is no consistent improvement with time for the small number of standard-risk T-cell patients, whereas there does seem to be a more favourable trend for high-risk T-cell patients. Overall, in UKALL X and XI, high-risk T-cell patients do not seem to fare significantly worse than high-risk B-cell lineage patients, whereas standard-risk T-cell patients do seem to experience more events than those with B-cell lineage ALL and standard-risk features. ALL97 and ALL97/99 were conducted from 1997 up to 2001, and subsequent follow-up takes this era to 2005. The comparisons within subgroups by the NCI risk group/lineage are shown in Table 4 . The benefit of dexamethasone and the lack of difference between thioguanine and mercaptopurine seem to be consistent across the groups.
Overall conclusions on prognostic factors
Throughout the time period from 1980 to 2001, features consistently associated with a more favourable prognosis include female gender, age between 1 and 9 years, WCC below 50 Â 10 9 cells/l, M1 status (5% marrow blasts) achieved by either day 8 or day 15 and more recently, a high hyperdiploid karyotype and the presence of the ETV6-RUNX1 fusion.
Discussion
The improvement in outcome seen in the United Kingdom in the early 1980s owed greatly to the collaboration with the then US CCG and adoption of one of its standard-risk protocols for all UK patients. This decision led to an 11% improvement in disease-free survival compared with the previous standard treatment in UKALL trials II-VII, and were at least as good for standard-risk patients as the result reported by the CCG using the same regimen. 4, 5 The subsequent trial, UKALL X, showed a continuing improvement in disease control, particularly for patients who received two intensification modules, although even patients treated with regimen A, with no intensification, had better OS than did patients who received identical treatment on arm B of UKALL VIII, largely because of reductions in induction and remission death rates. 6 In UKALL XI, disease control, especially prevention of bone marrow relapse, was better in patients who received three intensification modules compared with patients who received only two modules, but this advantage did not translate into improved OS. 7 It seems that those patients who relapse after only two intensification modules were more salvageable than patients relapsing after three. The result of the UKALL R1 relapse study showed an improvement in retrieving patients who relapsed more than 6 months off therapy with chemotherapy alone (5 year EFS of 57%), compared with other published series; this finding might, at least in part, explain why OS, but not EFS, in the United Kingdom during the era 1990-1997 was comparable with that reported by the CCG. 30 However, EFS in standard risk and more markedly in high-risk patients clearly lagged behind CCG and other cooperative group results. Although patients were being retrieved after relapse, the price of this extra therapy was greater toxicity.
In its initial guise, ALL97, which was conducted from 1997 to 2001, was a direct descendent of the UKALL X and UKALL XI regimens, the innovations being randomizations to examine the potential benefits of dexamethasone over prednisolone, and of thioguanine over mercaptopurine. Patients at very high risk of relapse, identified by chromosomal abnormalities or by the Oxford Hazard score, 24 were treated on a different regimen, HR1, 24 which was again a direct descendant of the UKALL X and XI regimens, although it did not include the steroid or thiopurine randomizations.
As a consequence of the comparisons of UK results 29 with the results obtained by the BFM 31 and CCG 32 groups, which confirmed that both UKALL X and XI gave unsatisfactory results for high-risk patients, the UK group decided to adapt the US CCG-style regimens CCG 1991 and 1961, which included stratification not only by initial risk factors (age, WCC) but also by early response to therapy. This phase of the trial was designated as ALL97/99. The EFS rates for both ALL97 and ALL97/99 were better than those of previous UKALL trials, as was the OS for ALL97/99. Both EFS and OS were significantly better in ALL97/99 than in ALL97.
The cumulative risk of isolated CNS relapse did not increase with the replacement of cranial irradiation in UKALL VIII and X by long-course i.t. methotrexate or by high-dose methotrexate with i.t. therapy in UKALL XI, or by the adoption of long-course i.t. methotrexate for all patients in ALL97 and ALL97/99. Isolated CNS relapse was reduced with the combination of high-dose methotrexate and i.t. methotrexate in UKALL XI for patients with an initial WCC of 50 or higher, but there was no advantage for disease-free survival or OS compared with i.t. therapy only.
A major improvement in CNS relapse rate was seen in ALL97/ 99, in which the rate was nearly halved for both standard and high-risk patients, regardless of which steroidFprednisolone or dexamethasoneFwas given, so that for all groups together, there was a highly significant reduction in CNS relapse risk. The best result was seen in ALL97/99 patients randomized to dexamethasone, in whom the actuarial isolated CNS relapse rate was only 1.8% at 5 years (95% CI: 0.4-3.2%) compared with 3.7% (1.7-5.7%) in patients randomized to prednisolone. These rates are much lower than those reported in previous trials that used cranial radiotherapy for CNS-directed therapy. 9, 33 The incidence of isolated CNS relapse in ALL97/99 was reassuringly low, even for subgroups perceived to be at higher risk of CNS relapse, such as those patients with WCC4100 Â 10 9 cells/l (4.8%) or with T-cell phenotype (3.8%), despite restricting the use of cranial radiotherapy only to patients with overt CNS disease (CNS 3, o5% of all patients).
The reasons for the failure of UKALL trials to significantly improve EFS in a manner seen by other cooperative groups in the period between 1980 and 1997 are not clear. Possible factors include the use of prednisolone at a dose of 40 mg/m 2 rather than 60 mg/m 2 or the use of dexamethasone; omission of daunorubicin from induction; suboptimal route of administration dosage and scheduling of asparaginase; the necessity of a lengthy gap (often over 3 weeks) in therapy to allow marrow recovery after week 5 and week 20 intensifications in UKALL X and XI; the form of UKALL X and XI intensifications; and the possible lack of strict and intensive compliance with the delivery of continuation therapy. The adoption of ALL97/99 resolved many of these potential issues, but in an uncontrolled manner; therefore, it is now possible to only speculate on which of these factors it might have been most relevant. The importance of adequate delivery of continuation therapy was addressed by Chessells et al. 34 who were able to show in UKALL X that patients who had one or more episodes of neutropenia (absolute neutrophil count o0.05 Â 10 9 cells/l) during the continuation phase had a better outcome than did patients who had no documented periods of neutropenia.
The current study, ALL2003, has built on the foundation provided by ALL97/99. The only substantial change in therapy from the latter trial has been the adoption of pegylated asparaginase throughout the induction and intensification phases. The trial examines the role of minimal residual disease detection as a means of characterizing an additional group of patients who might benefit from augmented therapy, as has previously been shown for morphological SER, 35 and a group of patients who can maintain a high expectation of cure even after therapy reduction, which, in this instance, is the omission of the second delayed intensification module. This trial should conclude in 2010, and its successor is now being designed.
During the periods of ALL97, ALL97/99 and ALL2003, it has become apparent that both short-and longer-term toxicities, particularly those associated with the use of dexamethasone, have become a major concern, as has the incidence of treatment-related mortality. These factors have been accentuated by the very high survival rates now being achieved. In addition, it seems possible to identify, early in therapy, a small group of patients for whom current regimens offer only a small prospect of cure and who might therefore be considered for additional early treatment and first remission bone marrow transplant. Thus, the next UK trial will most likely focus on toxicity reduction for the great majority of patients who seem to be readily curable using relatively simple, conventional, chemotherapy regimens, and intensification of therapy for a minority of patients who might yet prove to be curable if the benefits of very early identification and intensification, including bone marrow transplantation, can be realized.
